How Coologics Accelerated Trial Enrollment by 10x with Vector
Vector transformed a stagnant women's health study into a high-velocity enrollment engine, saving the sponsor over $500k in study-related costs.
Background
Coologics is a women's health startup developing a novel, drug-free treatment for yeast infections.
Unlike traditional treatments that rely on antibiotics, Coologics' vaginal cooling device is designed to provide symptom relief through controlled cooling temperatures.
The startup raised $3M in an oversubscribed seed round in April 2025, with a goal to complete its clinical trial and pursue FDA clearance as a prescription device.
The path to that outcome, however, was proving much more operationally complex than anticipated.
Challenge
The trial called for 55 evaluable patients to complete full enrollment, which Coologics had planned to achieve within 6-8 months.
When they engaged Vector at the end of the trial's 8th month, they had completed just 15% of enrollment.
To make matters worse, they were burning through seed capital at a significant clip. Funds that were allocated to go-to-market efforts, like building a telehealth platform, were being rapidly consumed by mounting CRO fees.
The trial had a clear patient recruitment problem. Coologics had fallen into the common trap of delegating recruitment to its CRO and sites, which were generating just 4-5 enrolled patients per month.
With just 21% of enrolled patients evaluable, the end to the sponsor's financial and operational pain was nowhere in sight.
Solution
Vector quickly went to work turning the trial's fragmented recruitment efforts into a high-performance enrollment funnel.
The first step was demand. The trial needed to generate targeted awareness with patients around the clinical sites that met the study criteria. Vector accomplished this in two ways:
Performance advertising campaigns on Facebook, Instagram, and Tiktok..
Search advertising campaigns that targeted patients around the sites actively searching for treatment options.
On social media, Vector leveraged authentic, IRB-approved video creative that leaned heavily into the study's women's health value proposition.
These videos perfectly balanced thumb-stopping visuals and scripts with compliance and credibility, leveraging OB/GYN thought leaders that held real sway with the study's target audience.
This strategy swiftly and dramatically increased the number of eligible, prescreened patients applying for enrollment.
Demand issues solved, Vector then got to work building the data and analytics stack that would Coologics complete transparency on not only campaign performance, but on performance of the trial as a whole.
This required pulling data from several different sources—including the CRO, ad and analytics platforms, and disjointed spreadsheets—to create a single, unified, real-time view of success.
With a live view of the most critical factors driving enrollment, Vector quickly noticed that conversion rate from eligible-prescreener-to-enrolled was quite low.
They were doing a great job getting eligible patients to apply for enrollment, but because the sites and CRO were not set up for volume outreach, there were downstream performance issues impacting total enrollment.
Vector resolved this "leaky bucket" by improving outreach workflows, enforcing speed-to-contact, and using data to relentlessly push the sites to improve conversion rates.
Results
After 12 weeks of working with Vector, Coologics saw substantial improvements across enrollment velocity and time-to-milestone, which resulted in substantial burn reduction in the forms of site and CRO fees.
Are you running a clinical trial and struggling with enrollment? Reach out to Vector to accelerate enrollment today.